# KLOW Clinic — Dose context from the source studies > Research-context dose ranges, routes, and half-life notes for the four KLOW components, drawn from the original studies. No human dosing recommendations. This page assembles the dose ranges, routes, and half-life numbers that appear in the source studies. The KLOW blend has no FDA-approved dose, no clinical dosing schedule, and no human pharmacokinetic profile. The numbers below are research-context only. ## The short version No validated human dose exists for the KLOW blend, and none is given here. The canonical research vial is 80 mg total — GHK-Cu 50 mg, BPC-157 10 mg, TB-500 10 mg, KPV 10 mg — a vendor convention, not the conclusion of a dose-response study. The four components were each studied at very different concentrations, in different species, by different routes, so their research doses cannot be summed or converted into a single KLOW protocol. A further complication is the pharmacokinetic mismatch: BPC-157 has a formal elimination half-life of under about thirty minutes, and the two tripeptides clear even faster, meaning one co-formulated vial cannot sustain all four arms at matched exposures simultaneously. The numbers below are research context drawn from the source studies, presented without any dosing guidance. ## How to read this page Each of the four KLOW components has been studied at a different set of doses, in different species, by different routes. The dose values below are reproduced from the original studies and are presented for research-context understanding only. No part of this page recommends a human dose, a research protocol dose, or any administration of any peptide to any subject. The blend itself has no published dose-response data because no controlled in-vivo study has tested it as a combination [1]. A brief reminder on units: micrograms per kilogram (μg/kg) and nanograms per kilogram (ng/kg) are mass-per-body-weight units common in rodent dosing; micromolar (μM) and nanomolar (nM) are concentration units common in cell-culture work; the canonical KLOW vial reports its components in milligrams per vial. These are not interchangeable, and the studies summarized below frequently use very different units depending on the model. ## KPV — dose ranges in the published work In vitro, KPV has been used at ten nanomolar in Caco2-BBE and HT29-Cl.19A intestinal epithelial cells and in Jurkat T cells, where it suppressed NF-kB activation and reduced multiple pro-inflammatory cytokines [2]. The human bronchial epithelial work tested KPV at zero point one to ten micrograms per milliliter against TNF-alpha or respiratory-syncytial-virus challenge, with dose-dependent inhibition of NF-kB activity and reduced IL-8 and eotaxin secretion [4]. The HaCaT keratinocyte work used fifty micrograms per milliliter against PM10 challenge [11]. In vivo, the murine colitis work used one hundred micromolar in drinking water — an oral / drinking-water exposure rather than a measured bolus — across DSS and TNBS models [2]. The traumatic-brain-injury work used a single one-milligram-per-kilogram intraperitoneal dose given thirty minutes after controlled cortical impact [6]. The PepT1-targeted nanoparticle formulation reported concentrations per protocol rather than as a free-peptide mass [5]. KPV is a tripeptide and is subject to rapid aminopeptidase degradation in plasma; targeted-delivery systems (nanoparticles and PepT1-mediated uptake in inflamed epithelium) substantially extend functional exposure in tissue. ## BPC-157 — dose ranges in the published work The Sikiric-laboratory rodent musculoskeletal program has converged on three dose magnitudes: ten micrograms per kilogram, ten nanograms per kilogram, and ten picograms per kilogram, typically delivered intraperitoneally. The Achilles tendon-to-bone study tested all three and reported functional, biomechanical, and histological recovery at the higher doses [12]. The medial collateral ligament study tested ten micrograms per kilogram and ten nanograms per kilogram intraperitoneally, one microgram of topical cream, and zero point one six micrograms per milliliter in drinking water — all four routes improved MCL healing at ninety days [13]. The gastrocnemius crush-injury work used the same micrograms-per-kilogram and nanograms-per-kilogram intraperitoneal doses plus topical cream over fourteen days [14]. BPC-157 has a reported plasma half-life of under thirty minutes in 2025 reviews [21]. It was originally characterized as the stable gastric pentadecapeptide on the basis of stability in human gastric juice, which supported the oral / drinking-water route in the rodent ligament study [13]. The 2025 systematic review of thirty-six studies confirms that essentially all published efficacy data uses the rodent ten-micrograms-per-kilogram or ten-nanograms-per-kilogram range; the three published human pilot studies report varied doses and routes that the review's authors explicitly decline to recommend for clinical use [20]. ## GHK-Cu — dose ranges in the published work The transcriptomic baseline is one to ten nanomolar in cultured fibroblasts, where Pickart and Margolina reported the ~31% genome-wide expression shift [7]. The COPD lung-fibroblast work used ten nanomolar GHK to reverse the emphysema gene signature and restore collagen-I contraction [24]. In vivo, the 2025 murine DSS colitis work used twenty milligrams per kilogram by oral gavage daily for fourteen days — substantially higher than the cell-culture concentrations, which is expected for an orally administered tripeptide subject to first-pass aminopeptidase activity [9]. Topical work spans formulations from creams (the 2002 human photodamage trial, twice-daily application for twelve weeks [23]) through composite hydrogels (the 2025 staphylococcus-infected wound work, applied topically [10]) and silver-nanoparticle conjugates (reported with minimum inhibitory concentrations of eight micrograms per milliliter against E. coli and S. aureus [25]). GHK is a tripeptide with a short reported in-vivo half-life in unmodified form; the cosmetic, hydrogel, and nanoparticle formulations exist to extend functional exposure at the application site. ## TB-500 and native Tβ4 — dose ranges in the published work The dermal wound-healing work — the strongest fragment-aware literature — used five micrograms of native thymosin beta-4 in fifty microliters of PBS, applied topically or intraperitoneally, in eight-millimeter full-thickness punch wounds in Sprague-Dawley rats [16]. The corneal alkali-burn work used five micrograms in five microliters of PBS twice daily as topical eye drops in 129 Sv mice [17]. The cardiac work used substantially larger doses of native protein. The 2004 myocardial-infarction paper administered intraperitoneal and intracardiac boluses of native thymosin beta-4 with a four-week follow-up [18]. The 2007 epicardial-progenitor-mobilization study used one hundred and fifty micrograms intraperitoneally every three days [19] — a chronic, repeated-dosing protocol that has no fragment-level analogue. Native thymosin beta-4 has a circulating half-life of approximately two hours in humans by ELISA. The TB-500 fragment is N-terminally acetylated to block aminopeptidase cleavage and improve in vitro stability, but the in vivo pharmacokinetics of the fragment specifically are not well characterized in the public literature. ## The blend itself The canonical KLOW research vial is eighty milligrams total: GHK-Cu at fifty milligrams (62.5% of mass), BPC-157 at ten milligrams (12.5%), TB-500 at ten milligrams (12.5%), and KPV at ten milligrams (12.5%) [1]. Some vendors offer a balanced variant at five milligrams per peptide for BPC-157, TB-500, and GHK-Cu with ten milligrams of KPV. There is no validated dose-response curve for the four-peptide combination because no controlled study has tested it. Vendor protocols typically recommend reconstitution in bacteriostatic water or sterile water and refrigeration at two to eight degrees Celsius with use within thirty days. The four peptides do not form a single chemical complex in a co-formulation; they are co-dissolved at fixed mass ratios. No published pharmacokinetic study has measured plasma exposure of the four components after administration of a KLOW co-formulation in any species. --- Four component literatures, read carefully — not a clinic, not a vendor, not a clinical recommendation.